Emibetuzumab

CAS NO.：1365287-97-3
Molecular Weight: 0
Update Date: 2026-04-24 14:59:02

What is Emibetuzumab?

Description

Emibetuzumab is a bivalent antibody that blocks HGF- and MET-receptor interaction, leading to MET internalization and degradation.

Clinical Use

A phase I study determined a tolerable dose for emibetuzumab to be 700–2000 mg as a monotherapy and in combination with erlotinib in NSCLC patients. It is currently being investigated in phase II in combination with erlotinib.

Properties of Emibetuzumab

form	Liquid
color	Colorless to light yellow

Safety information for Emibetuzumab

Computed Descriptors for Emibetuzumab

New Products

1,3-Dichloroacetone Ethylene Ketal 1-N-Boc-3-(aminoethyl)azetidine 4-N-BOC-AMINO-4-CARBOXYTETRAHYDROPYRAN AMino-(3-Methylphenyl)-acetic acid 3-AMINO-3-(2-CHLORO-PHENYL)-PROPIONIC ACID 4-Fluorophenylglycine 4, 4'-Ditolylamine (or) 4,4-Dimethyl Diphenylamine 2-Bromo-5-Chloropyridine 2-Picolinic acid N-oxide 4-Butyl Resorcinol 2-(2,4-Diaminophenoxy)ethanol Dihydrochloride 5-Bromo-2-Hydroxy-3-Nitro Pyridine 4-(4-(Dimethylamino)-1-(4-fluorophenyl)-1-hydroxybutyl)-3-(hydroxymethyl)benzonitrile Tetracaine Hydrochloride Ep Grade 2,2,2-Trichloroethyl chloroformate 5-Bromo-4-chloro-3-indolyl-β-D-galactopyranoside 4-Pentyn-1-ol 2-Bromo-6-fluoroaniline 5-fluoro-1,3-benzodioxole 5-Phenyl-[1,3,4]-thiadiazol-2-amine 2-Chloro-6-nitro benzothiazole 2-(Chloromethyl) quinazolin-4(3H)-one 2-Amino-4-phenyl-thiazole 4-Chloro-2-methyl quinoline